I

Instituto Dante Pazzanese de Cardiologia | Divisão de Pesquisa

Research site
(Unclaimed)
Location
Avenue Doctor Dante Pazzanese, number 500 8º andar da torre, Sao Paulo, Sao Paulo, Brazil
Site insights

Top conditions

Coronary Artery Disease (8 trials)

Coronary Disease (5 trials)

Myocardial Ischemia (4 trials)

Cardiovascular Diseases (4 trials)

Atherosclerosis (4 trials)

Top treatments

Warfarin
Olpasiran
Milvexian
Rosuvastatin
Sildenafil
Dabigatran
Mavacamten
Creatine
Tadalafil

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

4 of 27
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
Locations recently updated
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM)

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic...

Enrolling
Cardiomyopathy, Hypertrophic
Drug: Mavacamten
Other: Placebo

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Other: Placebo
Drug: Milvexian

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

The FANTOM II trial is intended to assess safety and performance of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.

Active, not recruiting
Coronary Artery Disease
Device: Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold

Trial sponsors

R

REVA Medical (3 trials)

Amgen logo

Amgen (2 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems